The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Alexion Pharmaceuticals (Inst); Sanofi (Inst); Seagen (Inst); Taris (Inst)
Research Funding - Ipsen (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst)
A multicenter chart review study of patients with metastatic pancreatic ductal adenocarcinoma receiving liposomal irinotecan after gemcitabine-based therapy.
 
Kenneth H. Yu
Consulting or Advisory Role - Ipsen
Research Funding - Bristol-Myers Squibb; Halozyme; Ipsen
 
Andrew Eugene Hendifar
Consulting or Advisory Role - Abbvie; Celgene; Ipsen; Novartis; Perthera
Research Funding - Ipsen
Travel, Accommodations, Expenses - Halozyme
 
Olatunji B. Alese
Consulting or Advisory Role - AstraZeneca; Conjupro Biotherapeutics; Exelixis; Ipsen
Research Funding - Acetylon Pharmaceuticals (Inst); Bristol-Myers Squibb (Inst); Five Prime Therapeutics (Inst); Ipsen (Inst); Taiho Pharmaceutical (Inst); Tesaro (Inst)
Travel, Accommodations, Expenses - Exelixis
 
Amber Draper
Honoraria - Wellstat Therapeutics
Consulting or Advisory Role - Array BioPharma
 
Maen Abdelrahim
Consulting or Advisory Role - Ipsen
Speakers' Bureau - Ipsen
 
Ethan Burns
No Relationships to Disclose
 
Gazala Naaz Khan
Honoraria - Bayer; Eisai
Consulting or Advisory Role - Bayer; Celgene; Eisai
Travel, Accommodations, Expenses - Bayer; Eisai
 
Paul Cockrum
Employment - Ipsen
Stock and Other Ownership Interests - Ipsen
Travel, Accommodations, Expenses - Ipsen
 
Rachel Bhak
Research Funding - Bayer (Inst); GlaxoSmithKline (Inst); Ipsen (Inst); Janssen Scientific Affairs (Inst); Mallinckrodt (Inst); Novartis (Inst); Pfizer (Inst); Seagen (Inst); Takeda (Inst)
 
Maral DerSarkissian
Employment - Analysis Group
Research Funding - AstraZeneca (Inst); GlaxoSmithKline (Inst); Ipsen (Inst); Janssen (Inst); Kiniksa (Inst); LivaNova (Inst); Mallinckrodt (Inst); Medtronic (Inst); Merck (Inst); Novartis (Inst); Novo Nordisk (Inst); Novo Nordisk (Inst); Pfizer (Inst); Sanofi/Regeneron (Inst); Seagen (Inst); Takeda (Inst); ViiV Healthcare (Inst)
 
Catherine Nguyen
Research Funding - AstraZeneca (Inst); Celgene (Inst); GlaxoSmithKline (Inst); Intercept Pharmaceuticals (Inst); Ipsen (Inst); Janssen (Inst); Kiniksa (Inst); Merck (Inst); Novartis (Inst); Novo Nordisk (Inst); Pfizer (Inst); Sanofi Pasteur (Inst); Shire (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Vertex (Inst)
 
Mei Sheng Duh
No Relationships to Disclose
 
Nathan Bahary
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Celgene; Exelixis; Thermo Fisher Scientific